Qingyi Yang

机构：North Sichuan Medical University, Pfizer (United States), Yunnan University, China Institute of Electronics, PRX Research · ORCID：0000-0001-5269-0494

发表论文 64 篇 · 总被引 3570 次 · h-index 27

代表论文

• A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 (2024 · Journal of Medicinal Chemistry · 被引 81)
• In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance (2024 · Science Advances · 被引 51)
• Probing the chemical ‘reactome’ with high-throughput experimentation data (2024 · Nature Chemistry · 被引 49)
• Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss (2023 · Journal of Medicinal Chemistry · 被引 29)
• Predictive Minisci late stage functionalization with transfer learning (2024 · Nature Communications · 被引 28)
• Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease (2025 · Journal of Medicinal Chemistry · 被引 27)